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Radical hysterectomy with pelvic lymphadenectomy remains the treatment of choice for women with Stages IA2 and IB1 carcinoma
of the cervix, and selected patients with Stage II endometrial cancer. Improvement in surgical techniqe, administration of
prophylactic antibiotics, thromboemolic prophylaxis, and advances in critical care medicine have resulted in lower operative
morbidity associated with this procedure. Major urinary tract complications such as ureteral injury or vesico-vaginal fistula are
now extremely rare (<1%). Five-year survival rates following this procedure vary according to a number of clinical and histologic
variables, and may be as high as 90% in women without lymph node metastases.

1. Introduction
The number of patients with early stage cervical cancer has
steadily increased with the widespread use of the Papanicolaou test for screening. In 2009, it is estimated that there will
be 11,070 new cases of cervical cancer in the United States
and nearly 500,000 new cases worldwide. Approximately
85% of newly diagnosed cervical cancer in industrialized
countries are expected to have localized or regional disease
[1, 2]. With the trend toward early detection, more patients
with invasive cervical cancer are diagnosed with early stage
disease and are candidates for primary surgical treatment
with radical hysterectomy and pelvic lymphadenectomy.
In 1898, Ernst Wertheim of Vienna described the
operation of radical hysterectomy including removal of the
parametrium and pelvic lymph nodes. In 1905, Wertheim
reported outcomes of the first 270 patients treated by radical
hysterectomy, which included an operative mortality rate of
18% and a major morbidity rate of 31%. Since that time,
radical hysterectomy with pelvic lymphadenectomy has been
performed with modifications in surgical technique as the
major surgical treatment for early stage invasive cervical
cancer [3, 4]. The use of prophylactic antibiotics, thromboembolic prophylaxis, administration of blood products,

and advances in postoperative and critical care medicine all
have lowered operative morbidity, and increased the survival
rate of cervical cancer patients treated with this operation.

2. Indications
The primary indication for radical hysterectomy with pelvic
lymphadenectomy is Stage I invasive cervical cancer. Early
invasive cervical cancer is divided by the International
Federation of Gynecology and Obstetrics (FIGO) Staging
System into Stage IA1 , which includes lesions invading the
cervical stroma to a depth of 3 mm, or less and a maximum
horizontal spread of 7 mm, and Stage IA2 , which includes
lesions with stromal invasion of 3–5 mm and a maximum
horizontal spread of 7 mm [5]. These diagnoses can be made
only after careful histologic evaluation of a conization specimen using an ocular micrometer to establish the depth of
stromal invasion. Patients with Stage IB1 cervical cancer have
microscopic evidence of stromal invasion >5 mm, horizontal
spread >7 mm or a clinically visible cervical lesion ≤4.0 cm
diameter. In patients with FIGO Stage IA1 cervical cancer
and no evidence of lymph vascular space invasion (LVSI),
conservative therapy with cervical conization or simple
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hysterectomy is appropriate [6–11]. However, patients with
Stage IA2 or Stage IB1 cervical cancer have a significant risk
of lymph nodal spread and should be treated by radical
hysterectomy and pelvic lymphadenectomy. Patients with
Stage IB2 or Stage IIA cervical cancer are treated with
chemoradiation or combined therapy in many institutions.
However, selected patients with Stage IB2 or IIA cervical
cancer may be treated with radical hysterectomy and pelvic
lymphadenectomy [12–14].
Radical hysterectomy may also be considered in the treatment recurrent cervical cancer. This procedure is appropriate
only in patients with small central recurrences, following
primary radiation of early stage disease. Maneo and colleagues, for example reported that radical hysterectomy is a
safe alternative to pelvic exenteration in patients with Stage
IB/IIA cervical cancer treated by primary radiation therapy,
who have a recurrence <4 cm in diameter without evidence
of ureteral obstruction or parametrial involvement [15].
Finally, radical hysterectomy with pelvic lymphadenectomy is indicated in patients with endometrial cancer and
endocervical involvement (FIGO Stage II disease). Boente
reviewed the clinical, surgical, and histopathologic data
from 202 patients with endometrial adenocarcinoma and
cervical involvement, and reported a survival advantage
for patients treated by radical hysterectomy with pelvic
lymphadenectomy when compared to total abdominal hysterectomy. This advantage was most notable in patients with
multiple high-risk factors [16]. Radical hysterectomy with
pelvic lymphadenectomy alone can be therapeutic in selected
patients with Stage II endometrial cancer, thereby avoiding
the morbidity associated with combination therapy [17].

Utero-ovarian ligament
and fallopian tube

Figure 3

3. Preoperative Evaluation
Prior to undergoing radical hysterectomy, patients should
have a thorough evaluation to insure that there are no major
medical contraindications to surgery. The anesthesiologist
should be aware of the potential for blood loss in patients
undergoing this procedure and should make preparation for
central venous access as well as the availability of properly
typed and cross-matched blood. A prophylactic antibiotic,
usually a first generation cephalosporin, is given within 30
minutes of skin incision [18]. Heparin 5000 units is given
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subcutaneously prior to surgery and three times daily in
the postoperative period for thromboembolic prophylaxis. In
addition, sequential compression devices (SCDs) are placed
on both lower extremities immediately prior to surgery, and
are left in place until the patient is ambulating [19].

4. Surgical Technique
(1) The patient is placed in supine position and the
abdomen and vagina are prepped. A foley catheter is
placed in the patient’s bladder, and SCD’s are placed
on both lower extremities.

Figure 6

(2) A vertical midline incision is made 3 cm above the
umbilicus and is extended inferiorly to the pubic
symphysis. A Bookwalter retractor is placed, and
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Figure 9

Figure 12

(6) The posterior leaf of the right broad ligament is
incised superiorly along the lateral pelvic wall to the
level of the infundibulopelvic ligament (Figure 2).
Figure 10

right-angle or body wall retractors are used to retract
the pelvic sidewalls.
(3) Prior to initiating the pelvic procedure, the entire
abdominal cavity is evaluated for evidence of
metastatic disease. This includes all surfaces of the
liver and diaphragm, the celiac plexus, omentum,
small, and large bowel surfaces as well as the
mesentery. Pelvic and para-aortic lymph nodes are
palpated, and any enlarged or suspicious nodes are
excised and sent for histologic evaluation.
(4) The bowel is packed into the upper abdomen using
warm, moist laparotomy sponges. Two 8-inch Kelly
Clamps are placed on the uterine cornua for retraction.
(5) The right round ligament is clamped, cut, and
ligated at the right lateral pelvic wall (Figure 1). The
anterior leaf of the right broad ligament is incised
inferiorly along the lateral pelvic wall for a distance
of approximately 3 cm.

(7) If the right ovary is to be preserved, the posterior leaf
of the right broad ligament is further incised parallel
and inferior to the infundibulopelvic and uteroovarian ligaments. The right utero-ovarian ligament
is then clamped, cut, and ligated, and the ovary is
placed in the right iliac fossa (Figure 3).
(8) If the right ovary is to be excised, the right infundibulopelvic ligament is clamped, cut, and doubly ligated
at the lateral pelvic wall. The right utero-ovarian
ligament is then clamped, cut, and suture ligated, and
the right tube and ovary are removed.
(9) Steps (5)–(8) are then repeated on the left side.
(10) The right retroperitoneal space is entered along the
lateral pelvic wall, thereby exposing the common
iliac, external iliac, and internal iliac arteries and
associated lymph nodal tissue.
(11) The ureter is identified, and two silk sutures are
placed in the adjacent medial peritoneum, thereby
pulling the ureter medially away from the iliac vessels
(Figure 4).
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with 2-0 silk ties, and transected. The superior vesical
artery is preserved (Figure 6).
(14) A vein retractor is placed on the medial aspect of the
external iliac artery and vein, and the obturator nerve
is identified. All lymph nodal tissue is removed from
the obturator fossa by sharp dissection (Figure 7),
placed in a separate container and submitted for
histologic analysis.
(15) Steps (10)–(14) are repeated on the left side.
(16) The right pararectal space and paravesical spaces are
defined by blunt dissection, and the lateral aspect of
the cardinal ligament containing the vascular web is
clamped, cut, and ligated with 2-0 silk ties (Figures 8
and 9). Ligation of the left vascular web is completed
in the same fashion.

Figure 13

(17) The right ureter is dissected from the medial peritoneum at the level of the uterosacral ligament
(Figure 10), and a 3/8 inch Penrose drain is placed
around the ureter (Figure 11). The ureter is dissected
laterally from the parametrial tunnel using right
angle clamps (Figure 12). The parametrial vasculature is ligated, and the ureter is rolled laterally out
of the tunnel. The right ureter is dissected free from
surrounding tissue until its entrance into the bladder
(Figure 13). The left ureter is then dissected free from
the left parametrium in the same fashion.
(18) The bladder is sharply dissected from the anterior
vagina, and the peritoneum between the uterus and
the rectum is incised. The anterior rectal wall is
reflected away from the posterior vagina.

Figure 14

(12) The lymph node dissection is begun by sharply
excising all lymph nodal tissue surrounding the
right common iliac, external iliac, and internal iliac
arteries. The lateral extent of the pelvic lymph node
dissection is defined by the genitofemoral nerve
(Figure 5). The external iliac and common iliac
arteries are retracted laterally, and lymph nodal tissue
surrounding the common iliac, external iliac, and
internal iliac veins is removed by sharp dissection.
Lymph nodal tissue from each of the major anatomic
sites (i.e., common iliac, external iliac, internal iliac)
is placed in separate containers and submitted for
histologic analysis.
(13) The anterior division of the internal iliac artery is
identified, and the uterine artery is isolated, ligated

(19) The uterus is elevated and the uterosacral ligaments
are clamped, cut, and tied (Figure 14). The anterior,
posterior, and lateral attachments of the uterus and
parametria have now been ligated. The paravaginal
tissue at the inferior margin of the dissection is
clamped, cut, and tied using curved Lainz clamps
(Figure 15).
(20) The vagina is transected approximately 3 cm below
the cervix and isolated bleeding sites on the vaginal
cuﬀ are ligated using 2-0 vicryl suture. The vagina is
closed using a continuous interlocking 0 vicryl suture
(Figure 16).
(21) Closed suction drains may be placed in both
retroperitoneal spaces at the discretion of the surgeon. These drains are brought out through the
anterior abdominal wall in each lower quadrant and
are sutured to the skin using 2-0 silk suture.
(22) If the ovaries are retained, they are suspended to the
lateral pelvic wall with 2-0 prolene, and titanium clips
are placed on the suture site for future identification.
(23) The abdomen is then closed in layers, using continuous 0 looped PDS in a modified Smead-Jones
technique.

Ayhan et al.
1991 [30]

Finan et al.
1996 [27]
Magrina et al.
1995 [28]
Benedetti-Panici
et al. 1993 [29]

Landoni et al.
2001 [13]
Zorlu et al.
1998 [25]
Abrao et al.
1997 [26]

—

—

84

270

—

375

—

302

—

10.4

115

229

—

—

219

109

4.0

201

—

—

290

Manchana et al.
2009 [21]

0.63

Wound
Infection (%)

529

480

Cai et al.
2009 [20]

Likic et al.
2008 [22]
Pikaart et al.
2007 [23]
Wu et al.
2006 [24]

# of Pts

Author

—

—

—

—

—

0.87

0.92

—

1.5

1.32

—

0.83

Ureteral
Injury (%)

—

—

—

—

—

2.6

—

—

—

—

—

0.83

Bladder
Injury (%)

—

—

—

—

—

8.7

—

—

—

—

—

0.21

Blood Vessel
Injury (%)

—

7.1

0.3

—

2.9

—

0.92

9.5

0.5

—

—

1.0

Urinary Tract
Fistula (%)

Table 1: Complications of Radical Hysterectomy.

16.2

—

—

—

9.2

—

14.7

19.9

7.5

—

14.5

12.9

Bladder
Dysfunction
(%)

—

4.8

0.8

4.4

—

—

2.8

—

1.5

—

—

—

Pulmonary
Embolism or
DVT (%)

6.4

21.4

0.8

—

—

—

11.9

7.8

1.0

—

9.3

5.8

Lympho-cysts
(%)

—

—

1.3

—

—

—

—

—

—

—

—

—

Intestinal
Obstruction
(%)
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Table 2: Five-year survival following radical hysterectomy for cervical cancer.
Author
Sartori et al.
2007 [31]

Ho et al.
2004 [32]

Ayhan et al.
2004 [33]

# of Pts

Stage

Size of
Lesion
(cm)

Depth of
Stromal
Invasion

Lymphvascular
Space Invasion

Lymph Node
Status

5-Year
Survival (%)

P value

454

IB-IIA

—

—

—

All

80

<.01

Negative
Positive

88
57

197

393

IB-II

IB

—

All

—

—

82

Inner 2/3
Outer 1/3

—
—
Negative
Positive

—
—
—
—
Negative
Positive

88.8
73.8
89.5
68.4
87.3
67.2

All

—

—

—

91

≤4

—
—
—
—

—
—
Negative
Positive

—
—
—
—

91.0
85.9
93.7
86.0

>4

Landoni et al.
2001 [13]

238

IB-IIA

All

—

—

—

79

Tsai et al.
1999 [12]

222

IB-IIA

All

—

—

—

76

≤4

—
—

—
—

—
—
Negative
Positive

88
67
87
71

>4

Lai et al.
1999 [34]

827

IB-II

<2

—

—

—

90.6

2–4
>4

—
—
Inner 2/3
Outer 1/3

—
—
—
—
Negative
Positive

—
—
—
—
—
—
Negative
Positive

82.7
69.1
90.3
74.9
86.3
76.5
87.3
68.2

5. Complications
Complications of radical hysterectomy with pelvic lymphadenectomy are summarized in Table 1. Bladder dysfunction and lymphocyst formation are among the most
common complications of radical hysterectomy and occur
in 5%–15% of cases in recent reports. Bladder dysfunction
results from extensive dissection of the ureters at the bladder
base and transection of the uterosacral ligaments, which
interrupts autonomic nerve supply to the bladder. In general,
more radical dissection results in a higher frequency of

.003
<.001
<.001

.012
.009

.0003
.0011
.0001

.0001
.0002
.0001

bladder dysfunction. However, preservation of the superior
vesical artery and blood supply to the distal ureter has
resulted in a marked decrease in the frequency of vesicovaginal and ureterovaginal fistula following radical hysterectomy.
Lymphocyst formation after radical hysterectomy and
lymphadenectomy is due to interruption of eﬀerent pelvic
lymphatics and can result in lymphedema, pelvic discomfort,
and infection as well as an increase in the frequency of
deep venous thrombosis and pulmonary embolism. Variation in the incidence of lymphocyst formation depends
on the extent of lymphadenectomy, retroperitoneal drain
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6. Survival
The 5-year survival in patients with early stage cervical
cancer treated with radical hysterectomy and pelvic lymphadenectomy varies between 80% and 95% according
to a number of clinical and histologic findings, and is
summarized in Table 2. Patients with low-risk early-stage
disease, undergoing radical surgical treatment have a survival
of nearly 100% [20]. However, patients with more advanced
disease have lower reported outcomes. Several risk factors
related to poor prognosis include large tumor volume, deep
stromal invasion, presence of lymph vascular space invasion,
and lymph node metastases [31–33]. A thorough analysis
of these factors is helpful in determining which patients
may benefit from postoperative therapy following radical
hysterectomy.

7. Summary
Figure 15

Radical hysterectomy with pelvic lymphadenectomy is the
treatment of choice for healthy women with stage IA2 IB1 cervical carcinoma. Women with nonbulky IB2 and
IIA cervical carcinoma, centrally recurrent disease, and
endometrial carcinoma with cervical involvement may also
be considered for surgical treatment by radical hysterectomy.
Improvements in surgical technique, prophylactic antibiotics, thromboembolic prophylaxis, administration of blood
products, and advances in postoperative and critical care
medicine all have lowered operative morbidity from this
procedure. Five-year survival rates in excess of 90% can be
achieved when this procedure is performed for the proper
indications.
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